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The effect of arachidonic acid on the A current (IA) has been studied in dissociated bullfrog neurons under whole-cell voltage-clamp conditions. 
Arachidonic acid reduced IA in a dose-dependent and reversible manner without a shift in the prepulse inactivation voltage-current relation. 1.75 
PM inhibited IA by 50%, and higher concentrations caused a total suppression. In addition, arachidonic acid increased the M-current (I,), a different 
potassium current that does not inactivate. Neither indomethacin or nordihydroguaiaretic acid, cyclooxygenase and lipoxygenase inhibitors 
respectively, prevented IA reduction. In contrast, nordihydroguaiaretic acid prevented Z, enhancement. Eicosatetraynoic acid, an arachidonic acid 
analog that cannot be metabolized, also reduced IA. These results uggest that arachidonic acid metabolism isnot required to suppress IA. 
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1. INTRODUCTION 
Modulation of ionic channels plays a fundamental 
role in controlling the activity of both excitable and 
non-excitable cells [1,2]. In the last few years, it has 
become clear that arachidonic acid and its metabolites 
should be included in the list of second messengers in- 
volved in ion channel modulation [3,4]. Arachidonic 
acid is produced in normal conditions in response to 
hormones or neurotransmitters, or in abnormal condi- 
tions such as ischemia, epilepsy or stroke [5,6]. Upon 
liberation from membranes (by a GTP-binding protein 
and/or calcium mediated stimulation of phospholipase 
A, [7], or sequential participation of phospholipase C 
and phospholipase D or diglyceride lipase [S]), ara- 
chidonic acid can exert its action directly on the channel 
(or a closely associated component) [3], or indirectly 
through its numerous metabolic products, including 12 
and 5 lipoxygenase metabolites [9-l 11, or through acti- 
vation of protein kinase C and oxygen radical produc- 
tion [12]. 
tricular myocytes may be mediated by protein kinase C 
[19]. However, this is in sharp contrast to the results of 
Tohse et al. [20] who did not observe a significant reduc- 
tion in the response to phorbol esters in the same prep- 
aration, and to the augmentation observed in the re- 
sponse to phorbol myristate in rabbit atria1 myocytes 
[23]. In addition, in hippocampal neurons, high concen- 
trations of phorbol dibutyrate do not affect IA [24]. 
Here, blockade of the A-current by arachidonic acid 
in bullfrog sympathetic neurons is described. Ara- 
chidonic acid reduces IA at low concentrations, in a 
dose-dependent and reversible manner, indicating that 
arachidonic acid is a plausible second messenger for 
neurotransmitter mediated IA modulation. 
2. EXPERIMENTAL 
Bullfrog sympathetic neurons were isolated from lumbar VIIIth, 
The A-current (IA) is a transient voltage-dependent 
potassium current that has been implicated in control 
of cell excitability [ 131. Several neurotransmitters modu- 
late IA in neurons [l&18] and other excitable cells [ 19- 
221. The second messenger system involved in these re- 
sponses has not been identified yet. It has been sug- 
gested, based on the action of phorbol esters, that the 
reduction of the transient outward current in rat ven- 
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IXth and Xth ganglia by enzymatic treatment and trituration as previ- 
ously described [25] and used after l-7 days in culture. Currents were 
recorded at room temperature (22-24“C) in continuous whole-cell 
voltage-clamp mode using a List EPC7 amplifier. 7O-80% series resis- 
tance was compensated. Fire-polished, filamented hard glass elec- 
trodes, with a tip diameter of -3.3 ,um, were used. The total access 
resistance varied from 2 to 10 MR. The intracellular solution was 90 
mM K aspartate, 20 mM KCl, 1.5 mM MgCl,, 1.5 mM Na,ATP, 5 
mM HEPES, 0.2 mM EGTA, 60 PM CaCl, (80 nM estimated free 
calcium), and 0.2 mM Na,GTP. The pH was adjusted to 7.2. Neurons 
were constantly perfused with extracellular solution, which was 115 
mM NaCl, 2.5 mM KCI, 1 mM MgCl, 5 mM HEPES and 10 mM 
glucose (pH 7.2). To reduce contamination by other currents, 2mM 
MnCl, (a calcium channel blocker), 1 mM TEA (a potassium channel 
blocker), 0.2 mM d-tubocurarine (ablocker of some calcium activated 
potassium channels) and 200 nM TTX (a sodium channel blocker) was 
added. This solution caused a 16 mV junction potential that was 
subtracted in the voltages reported. A suction pipette-150pm in diam- 
eter was positioned -150pm from the cell to exchange solutions around 
the neuron studied. 
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Arachidonic acid was from Calbiochem (San Diego, CA), eicosa- 
tetraynoic acid (ETYA) was from Biomol (Plymouth Meeting, PA) 
and the rest of the chemicals were from Sigma (St Louis, MO). Ara- 
chidonic acid, ETYA, indomethacin and nordihydroguaiaretic acid 
were prepared from a stock solution in dimethyl sulfoxide (DMSO), 
to a final DMSO concentration of less than 0.25%. At this concentra- 
tion, DMSO did not have an appreciable effect on the M- or A- 
currents. DMSO was dehydrated with ‘molecular sieves’ (8-12 mesh 
size, 3 Angstroms nominal diameter ) (Fisher, Fair Lawn, NJ). Stock 
solutions (100 mM) of arachidonic acid and ETYA were kept at 
-80°C in sealed amber vials under nitrogen. 
Currents were digitized and acquired on line via a Data Translation 
DT2801A interface (4096 current levels) and stored in an IBM com- 
patible computer, using software written in ASYST language (ASYST 
1.53; Macmillan Software Company, NY). Currents were filtered with 
an 8 pole Bessel filter (Frequency devices, model 902) at l/2 the 
acquisition frequency (typically between 200 and 500 Hz). 
Analysis was done using Sigmaplot 4.1 (Jandel Co., Corta Madera, 
CA). Results are expressed as mean + S.D. (n = number of experi- 
ments). 
3. RESULTS 
Fig. 1A shows the protocol used to reveal the A- 
current (IA). The membrane potential was held at -40 
mV At this holding potential the M-current (ZM) is the 
predominant current because it does not inactivate [26]. 
An inward current relaxation (reflecting the closure of 
A, -4OmV I 
-60 
1 
50 ms 
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M-channels) was evoked by a 1 s voltage step to -60 
mV. When the potential was returned to -40 mV, an 
outward current relaxation was revealed as M-channels 
reopened. Increasing 1 s voltage steps were imposed 1 
s after the first voltage jump. When the second voltage 
step was more negative than -70 mV the M-current 
activation relaxations were superimposed on the fast 
inactivating A-current, which increased as the hyperpo- 
larizing voltage pulse removed more inactivation. The 
current during the first repolarization was subtracted 
from the current during the second repolarization to 
isolate IA (Fig. 1B). This protocol caused an underesti- 
mation of the size of Z,. 
Prepulse inactivation curves were constructed by 
plotting the peak current after subtraction versus the 
second prepulse voltage (Fig. 1C). The Boltzman rela- 
tion Z/I,, = l/(1 + exp(( V,,,- VJS ) was fitted to data 
obtained in calcium bath solution (open circles) with 
V 0.5 = -93.1 _+ 0.35 mV and S = -7.1 + 0.31 mV (n = 
12), and with Vo.5 = -81.1 + 0.54 mV and S = -6.6 + 
0.48 mV (n = 3 1) when calcium was replaced by manga- 
nese and 1 mM TEA, 0.2 mM d-tubocurarine and 200 
nM TTX was added (filled circles). A similar shift in the 
inactivation characteristics caused by divalent cations 
has been previously described in other neuronal and 
-140 -100 -60 
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Fig. 1. Inactivation characteristics of IA under whole-cell voltage- 
clamp conditions. (A) Removal of inactivation protocol. The relaxa- 
tion upon the tirst 1 s -20 mV voltage jump was subtracted from the 
relaxation evoked upon repolarization after the second (test) voltage 
step. (B) Subtracted currents from records in A. (C) Average inactiva- 
tion characteristics of Z, in calcium containing bathing solution (open 
circles, 12 neurons) and manganese containing bathing solution (fiBed 
circles, 31 neurons). The half activation point of the Boltzman distri- 
bution shifted from -93 to -81 mV (see section 3). The bars are the 
means f S.D. 
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Fig. 2. Arachidonic acid suppress IA and enhances ZM. (A) Is, relaxation evoked at -40 mV by a 1 s pre-pulse to -60 mV (dotted lines), and IA 
revealed by a 1 s pre-pulse to -110 mV (which removes IA inactivation) in control (a), in the presence of 20 PM AA (b), and after AA removal 
(c). Horizontal dotted line indicates zero current level. Bovine serum albumin (1.0 mg/ml) was used to remove AA from the bath. A suction pipette 
was positioned 150 pm from the cell to exchange the solutions. This set up was important to reveal the effect of AA at low concentrations [25]. 
(B) Time course of IA inhibition (triangles) and Z, enhancement by AA in the same cell as in A. Is, was estimated as the steady-state current at 
-40 mV, and Z* as the peak current evoked after a 1 s pre-pulse to -110 mV, subtracted from the current evoked after a 1 s pre-pulse to -60 mV 
to reduce the contribution of Zt,, and leak. This protocol causes an underestimation of the size of IA. (C) Concentration dependent relation for 
AA-mediated Z, inhibition. The hyperbolic relation Max.[AA]/([AA] + IC,,) was fitted to the data (solid line), with Max = 100.0 + 4.31%, and 
I&, = 1.75 f 0.42 ,uM. The circles represent he average (from lower to higher [AA]) of 7,3, 11, 12 and 2 independent experiments. Vertical bars 
are standard deviations of the mean. (D) Activation (triangles) and inactivation removal (circles) of IA in control (open symbols) and in the presence 
of 10 pM AA (filled symbols). Activation values were measured at the different potentials, stepping from a holding potential of -105 mV. 
Inactivation removal was measured at -40 mV as the peak current evoked after 1 s prepulses to the different potentials, and after subtracting the 
current evoked by a 1 s pre-pulse to -60 mV, to reduce the contribution of Zr+ 
cardiac A-currents [27,28]. All the experiments pre- 
sented below were performed in manganese xtracellu- 
lar solution. 
Fig. 2A (continuous trace) shows the transient potas- 
sium A-current evoked by a 1 s prepulse to - 110 mV. 
After subtracting the M-current relaxation, the mean 
peak current was 1,532 f 854 pA (n = 32) (mean f 
SD.). The M-current relaxations were observed practi- 
cally in isolation when the prepulse potential was -60 
mV (Fig. 2A, dotted trace). Addition of arachidonic 
acid (AA) to the bath caused the suppression of IA and 
the augmentation of Ir,, (Fig. 2A, center). The effect of 
AA on Ir,,, has been described elsewhere [25,29-311. 
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After AA was removed from the bath, IA and Zr,, 
returned to levels comparable to control (Fig. 2A, left). 
Fig. 2B shows that both 1, suppression (triangles) and 
ZM increase (circles) followed a parallel time-course. The 
reduction of IA by AA was dose-dependent (Fig. 2C). 
The concentration estimated to cause 50% reduction 
was 1.75 PM (see legend of Fig. 2C). The reduction of 
IA was not due to a shift of the voltage-dependency of
inactivation removal (Fig. 2C, circles). The effect on the 
activation curve was also consistent with a lack of volt- 
age shift (Fig. 2C, triangles). The protocol used to iso- 
late I, was not adequate to study the kinetics of IA, due 
to imperfect subtraction of the contribution of IM and 
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contamination by other currents. However, major AA did not increase the residual ZM, but reduced IA by 
changes in the inactivation kinetics were not observed. 79.9 f 7.2% (n = 3). 
Arachidonic acid can be metabolized mainly through 
the cyclooxygenase and the lipoxygenase pathways [6]. 
Neurons were preincubated in the presence of 10 PM 
indomethacin, a cyclooxygenase blocker. The addition 
of 20 ,uM AA in the presence of this drug caused sup- 
pression of IA and increase of IN. IA was reduced by 83.0 
+ 9.7%, and IM increased by 38.0 + 26.7% (n = 6). The 
role of the lipoxygenase pathway was investigated next. 
The M-current provides a convenient internal control, 
because it has been shown that blocking the lipoxyge- 
nase pathway causes &,, reduction, and that AA-medi- 
ated &,, enhancement can be prevented by lipoxygenase 
inhibitors [31]. In the presence of 10 ,uM nordihy- 
droguaiaretic acid, a lipoxygenase inhibitor that almost 
suppressed IM completely at this concentration, 5 ,uM 
10 ,uM eicosatetraynoic acid (ETYA), an AA analog 
with triple instead of double bonds that is not metabol- 
ized by the lipoxygenase or the cyclooxygenase path- 
ways [6], suppressed Z, (Fig. 3C). IA was reduced by 98.6 
f 2.1% (n = 6), and &, was reduced by 56.9 + 16.8% 
(n = 6). The reduction of &,, was expected because 
ETYA inhibits the lipoxygenase pathway [6]. Taken 
together, these results suggest hat AA does not need to 
be metabolized to exert its effect on 1,. 
4. DISCUSSION 
Modulation of A-currents can be classified in two 
groups: (a) modulation associated with shifts in the volt- 
age-dependency, and (b) reduction or increase of the 
current with no apparent change in the voltage-depend- 
ency. The first group includes the action of divalent 
cations in neuronal [271, and this paper and cardiac ceils 
[28], and the modulation by muscarinic [I 5,171 and by 
GABA, agonists [18] in brain neurons. The second 
group includes the reduction induced by al-adrenergic 
agonists in dorsal raphe neurons [14], atria1 [22] and 
ventricular [19], but see [20] myocytes, and the effect of 
arachidonic acid presented in this paper. 
Indomethacine 2O pM AA 
B 5pMAA 
J 
10 /,LM ETYA 
Fig. 3. Pharmacology of I, modulation. (A) 10 PM indomethacin (a 
cyclooxygenase inhibitor) did not prevent I, blockade or Z, enhance- 
ment by AA. Left, current evoked with the same protocol as in Fig. 
2 in the presence of indomethacin. Right, effect of 20 PM AA in the 
presence of indomethacin. Horizontal scale bar is 100 ms, and vertical 
bar is 0.17 nA. Horizontal dotted line indicates zero current level. (B) 
10 PM NDGA (a lipoxygenase inhibitor) prevented Z, enhancement 
by AA, but not IA suppression. Left, control. Right, after addition of 
AA. Vertical bar in A correspond to 0.125 nA. (C) 10 PM ETYA (an 
AA analog) reduced I,,, and suppressed IA. Left, control. Right, in the 
presence of ETYA. Vertical scale bar in A correspond to 0.8 nA. 
The AA concentration that caused 50% reduction of 
IA (1.8pM) is comparable to the concentration (2.8 PM) 
that cause 50% of the maximal &, enhancement in these 
neurons [25]. These concentrations are on the same 
order of magnitude than the J&, of several enzymes 
involved in the AA cascade [6], and positions AA as a 
plausible second messenger mediating 1, inhibition. The 
possibility that AA may be involved in IA inhibition by 
al adrenergic agonists in atria1 myocytes [22] is very 
attractive, because there is indirect evidence that 
adrenergic receptor activation causes production of AA 
in atrium [32]. 
AA metabolism may not be needed to inhibit I,, 
because the effect was not prevented by the cyclooxyge- 
nase inhibitor indomethacin or the lipoxygenase inhibi- 
tor NDGA. Conversely, the non-metabolizable analog 
ETYA, which can substitute for AA in the direct activa- 
tion of potassium channels in smooth muscle cells [33], 
mimicked the response. Preliminary experiments ug- 
gest that mediation of AA action by protein kinase C 
(PKC) is unlikely, because maximal concentrations of 
phorbol dibutyrate that activates PKC and reduces I,, 
reduced 1, very little or not at all. Further experiments 
are necessary to establish the mechanism of action of 
AA on IA. Intracellular calcium, which is known to 
reduce IA [34], and free oxygen radicals [12] are poten- 
tial mediators for AA action. However, the participa- 
tion of free radicals is unlikely, because the experiments 
were performed in the presence of manganese, which 
has free radical scavenging properties [35]. Although the 
purity of AA used in this study was greater than 99%, 
187 
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the contribution of peroxides to IA suppression cannot [17] Akins, P.T., Sunneier, D.J. and Kitai, S.T. (1990) Nature 344, 
be ruled out. 240-242. 
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